Amneal PharmaceuticalsAMRX
Buy moreBuy more on a dip to our buy price, which is under Friday's $21.
- 8 good· Earnings beat
- 3 to watch· Revenue slowing
$21.13−0.26 (−1.22%)
After hours $21.78 +3.2% · 6:11 PM ET on Friday
Price at 3:59 PM ET on Friday
Market closed · opens in 22h 24mNext open: Monday, Nov 23, 9:30 AM ETNYSE · Healthcare · Health Care · Mid-size company
The price we'd buy AMRX at comes with a free account
It also has the whole brief, the scorecard and how the call has moved.A free account gets it on three stocks you pick, plus three long research reports a month.
What would change it
Sources
- From the 10-Q for the quarter to Sep 30, reported Nov 3
- Yahoo Finance daily closes to Nov 20
Could move it to Keep
Next report
Shrinking
sales
Compared with the S&P 500
9 points
worse in one day
21 points
worse in five trading days
+83.5% in a yearsince Nov 20, 2025
The news behind our call
FDA approval lets Amneal sell generic lanreotide immediately.
How AMRX's risks changed
10-Q filed Nov 9 against its 10-K from Feb 27
1from an earlier 10-Q
What changed
Overview
Key figures
- Revenue (TTM)
- $3.2B
- Revenue growth, 1 year
- +8.9%
- Net income
- $133M
- EPS (diluted)
- $0.40
- Gross margin
- 40.0%
- Operating margin
- 16.7%
- Return on equity
- 70.0%
- Return on capital
- 15.4%
- Debt / equity
- 5.12
- Current ratio
- 1.87
- Buyback yield
- -4.13%
Key facts
- Company value
- $7.4B
- Price / last year's earnings
- 52.8×
- Today's range
- 21.0721.70
- Past year's range
- 11.8121.88
- Yesterday's close
- $21.39
- Swings vs the market
- 1.3×about the same